Highlights
• The company will be primarily invest in the development of new manufacturing technologies across cell and gene therapies, vaccines, viral vectors and proteins
• COVID-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery said Resilience founder Nelsen
Resilience, a biopharmaceutical ....
Tags : Resilience, US healthcare, Robert Nelsen, FDA, COVID-19, ,
comments (0)